Cutting edge research could mark the end of passing painful kidney stones.

About Kidnease

Passing a kidney stone is excruciatingly painful, it has often been compared to birthing a child.

Cutting edge research from the Lawson Institute and the University of Guelph could mark the end of passing painful kidney stones.

Kidnease is a product developed by SP Nutraceuticals Inc. that comes from the scientific research of the Lawson Institute in collaboration with the University of Guelph.  The discovery is a plant-derived molecule that can break up the most common type of kidney stone without causing harm to the rest of the body.

SP Nutraceuticals Inc. has been granted in international PCT patent for the use of Kidnease for the treatment and prevention of nephrolithiasis (kidney stones).

From the peer reviewed article summary: “Through functional screening, the therapeutic potential of a novel compound commonly known as arbutin that specifically binds to oxalate, a key component of kidney calculi, was identified. Through isothermal titration calorimetry, high-performance liquid chromatography and atomic force microscopy, arbutin was determined to interact with calcium and oxalate in both free and bound states, disrupting crystal lattice structure, growth and crystallization. When used to treat patient urine samples, arbutin significantly abrogated calculus formation in vivo and outperformed potassium citrate in low pH urine conditions, owing to its oxalate-centric mode of action.”

Kidnease has been tested in a preclinical model and evidenced both safety and efficacy. 

Kidnease is now in a phase I human safety clinical trial evaluating the safety of multiple dose forms.


To read the peer reviewed published research, please click here.

Information about our phase I clinical trial can be found here.